Skip to main content
Private placement pulls in $5M for PAVmed

A private placement of senior notes and Series S warrants involving Scopia Holdings has brought in $5 million for New York-based PAVmed. The company, which makes the PortIO intraosseous infusion system and the CarpX device for treating carpal tunnel syndrome, will use the proceeds for accelerating its growth plan and pipeline of products to commercialization.

Full Story: